STOCK TITAN
  1. Home
  2. ASLN

ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

ASLN NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
86 253 sessions, September 1, 2023 to September 4, 2024
Largest daily move
+160.8% close of March 11, 2024
1-year change
-96.4% closing prices, September 1, 2023 to September 4, 2024
1-month change
+0% closing prices, August 2, 2024 to September 4, 2024

Company Description

ASLN declined 96.4% in the 12 months to September 4, 2024. The last closing price was $0.6000.

This page collects what Stock Titan holds for ASLN, including price data and latest news.

Stock Performance

Chart
$0.6000
No recent trading
Last close: September 4, 2024
-96.4%
1 year to September 4, 2024
-
Market Cap
-
Shares outstanding

ASLAN Pharmaceuticals (ASLN) closed at $0.6000 on September 4, 2024. In the 12 months to September 4, 2024, the price lost 96.4%.

See what a $1,000 investment in ASLN would be worth today

Average down calculator for ASLN

ASLN Metrics & Rankings

September 2024
+0.0%
—
2024
-85.6%
—

Price returns through September 4, 2024. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
-36.95%

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

-45.88%

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

-12.17%

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

-3.81%

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

+4.30%

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

earnings
-2.87%

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

conferences clinical trial
+0.61%

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

+0.66%

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

conferences
+0.21%

ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference

-11.13%

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

clinical trial

ASLAN Pharmaceuticals has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, conferences, clinical trial. View all ASLN news →

SEC Filings

No SEC filings available for ASLN.

Frequently Asked Questions

What is the current quoted price of ASLAN Pharmaceuticals (ASLN)?

ASLAN Pharmaceuticals (ASLN) has no recent trading. Its last close was $0.6000 on September 4, 2024.